secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001213900-24-097777
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX Q3 net income $9.6M on warrant revaluation; DFO Phase 2 enrollment complete, CF topline pushed to H1 2026
--------------------------------------------------------------------------------

- Cash $24.7M as of Sep 30, 2024; company expects runway into Q4 2025.
- R&D expenses $7.3M (+30% YoY); G&A $3.2M (+45% YoY); $801K goodwill impairment.
- Net income $9.6M vs net loss $7.9M in Q3 2023 due to warrant fair value change.
- BX211 DFO Phase 2 patient enrollment done; topline results expected Q1 2025.
- BX004 CF Phase 2b topline delayed to H1 2026; manufacturing delays resolved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390024097777/0001213900-24-097777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390024097777/ea0221192-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-097777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer